Vanda Pharmaceuticals Inc.
VNDA Real Time Price USDRecent trades of VNDA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in VNDA holdings by institutional investors
Quarterly net insider trading by VNDA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$40,000 Oct 19, 2021 Issue: Pharmacy
-
$40,000 Jul 19, 2021 Issue: Pharmacy
-
$40,000 Apr 16, 2021 Issue: Pharmacy
-
$40,000 Jan 19, 2021 Issue: Pharmacy
-
$40,000 Oct 14, 2020 Issue: Pharmacy
-
$40,000 Jul 16, 2020 Issue: Pharmacy
-
$40,000 Apr 20, 2020 Issue: Pharmacy
-
$40,000 Jan 21, 2020 Issue: Pharmacy
VNDA Estimated quarterly lobbying spending
VNDA Revenue by Segment or Geography
New VNDA patent grants
-
Patent Title: Liquid tasimelteon formulations and methods of use thereof Oct. 21, 2025
-
Patent Title: Liquid tasimelteon formulations and methods of use thereof Oct. 14, 2025
-
Patent Title: Method of improving sleep Sep. 30, 2025
-
Patent Title: Methods of treating multiple sclerosis Sep. 23, 2025
-
Patent Title: Pharmaceutical combination comprising a selective s1p Sep. 09, 2025
-
Patent Title: Method for improving or enhancing cognition Sep. 02, 2025
-
Patent Title: Methods of treating multiple sclerosis Jul. 15, 2025
-
Patent Title: Dosing regimen for a selective s1p1 receptor agonist Jun. 24, 2025
-
Patent Title: Method of treatment with tradipitant Jun. 03, 2025
-
Patent Title: Highly purified pharmaceutical grade tasimelteon May. 20, 2025
-
Patent Title: Treatment of circadian rhythm disorders Jan. 21, 2025
-
Patent Title: Pharmaceutical dosage system Jan. 21, 2025
-
Patent Title: Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone Nov. 19, 2024
-
Patent Title: Highly purified pharmaceutical grade tasimelteon Jul. 30, 2024
-
Patent Title: Methods of treating multiple sclerosis Apr. 09, 2024
-
Patent Title: Treatment of circadian rhythm disorders Mar. 05, 2024
-
Patent Title: Method and composition for treating a serotonin receptor-mediated condition Jun. 05, 2018
-
Patent Title: Treatment of circadian rhythm disorders Jan. 02, 2018
-
Patent Title: Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide Dec. 26, 2017
-
Patent Title: Treatment of circadian rhythm disorders Nov. 14, 2017
-
Patent Title: Treatment of circadian rhythm disorders Aug. 15, 2017
-
Patent Title: Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone Jul. 18, 2017
-
Patent Title: Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide Apr. 11, 2017
-
Patent Title: Treatment of circadian rhythm disorders Jan. 24, 2017
-
Patent Title: Treatment of circadian rhythm disorders Jan. 10, 2017
-
Patent Title: Antipsychotic treatment based on snp genotype Oct. 04, 2016
-
Patent Title: Method and composition for treating a serotonin receptor-mediated condition Sep. 20, 2016
-
Patent Title: Antipsychotic treatment based on drd2 or ankk1 snp genotype Aug. 09, 2016
-
Patent Title: Antipsychotic treatment based on snp genotype May. 03, 2016
-
Patent Title: Antipsychotic treatment based on drd2 or ankk1 snp genotype Jan. 26, 2016
-
Patent Title: Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide Dec. 15, 2015
-
Patent Title: Method of treatment based on polymorphisms of the kcnq1 gene Oct. 13, 2015
-
Patent Title: Methods for the administration of iloperidone Sep. 22, 2015
-
Patent Title: Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms Jul. 14, 2015
-
Patent Title: Method of predicting a predisposition to qt prolongation Jul. 07, 2015
-
Patent Title: Method of predicting a predisposition to qt prolongation Jul. 07, 2015
-
Patent Title: Method of predicting a predisposition to qt prolongation Jul. 07, 2015
-
Patent Title: Method of predicting a predisposition to qt prolongation Jul. 07, 2015
-
Patent Title: Treatment of circadian rhythm disorders Jun. 23, 2015
-
Patent Title: Antipsychotic treatment based on drd2 or ankk1 snp genotype Jun. 16, 2015
-
Patent Title: Method of treatment based on polymorphisms of the kcnq1 gene Apr. 07, 2015
-
Patent Title: Stable dosage formulations of imidazolylalkyl-pyridines Oct. 21, 2014
-
Patent Title: Treatment of circadian rhythm disorders Jul. 22, 2014
-
Patent Title: Method and composition for treating an alpha adrenoceptor-mediated condition May. 20, 2014
-
Patent Title: Prediction of qt prolongation based on snp genotype Feb. 18, 2014
-
Patent Title: Method and composition for treating a serotonin receptor-mediated condition Dec. 31, 2013
-
Patent Title: Methods for the administration of iloperidone Nov. 19, 2013
-
Patent Title: Ruthenium (ii) catalysts for use in stereoselective cyclopropanations Oct. 15, 2013
-
Patent Title: Ruthenium (ii) catalysts for use in stereoselective cyclopropanations Jan. 17, 2012
-
Patent Title: Ruthenium(ii) catalysts for use in stereoselective cyclopropanations Jul. 13, 2010
Federal grants, loans, and purchases
- $162,771 2024-10-01 00:00:00 Agency: Department of Veterans Affairs
- $0 2024-09-05 00:00:00 Agency: Department of Veterans Affairs
- $0 2024-08-24 00:00:00 Agency: Department of Veterans Affairs
- $162,771 2024-01-17 00:00:00 Agency: Department of Veterans Affairs
- $81,597 2023-08-14 00:00:00 Agency: Department of Veterans Affairs
- $0 2022-09-22 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $32,891 2022-06-09 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $32,891 2022-03-11 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $34,999 2021-12-08 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2021-05-04 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded to VNDA from public contracts
Recent insights relating to VNDA
Recent picks made for VNDA stock on CNBC
ETFs with the largest estimated holdings in VNDA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $VNDA stock a Buy, Sell, or Hold?
- What is the price target for $VNDA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $VNDA stock?
- Who owns the most shares of $VNDA stock?
- What funds own $VNDA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VNDA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
- Address Washington, DC
- Market Cap 283.7 million
- Employees 368
- Industrial Classification Pharmaceutical Preparations